Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 50 mg; metformin hydrochloride 1000 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 50 mg; metformin hydrochloride 500 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - losartan potassium losartan potassium - film coated tablet - 12.5 & 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - losartan potassium losartan potassium - film coated tablet - 12.5 & 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - famotidine - film coated tablet - 20 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - famotidine - film coated tablet - 40 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - cyproheptadine hydrochloride - tablets - 4 mg milligram